Pentagon and Anthropic Clash Over AI Safeguards in National Security Use 
Google Halts UK YouTube TV Measurement Service After Legal Action 
Climate Adaptation at Home: How Irrigreen Makes Conservation Effortless 
Toyota Retains Global Auto Sales Crown in 2025 With Record 11.3 Million Vehicles Sold 
The Maire - EuroChem Case: Three Lessons for Global Business 
NVIDIA, Microsoft, and Amazon Eye Massive OpenAI Investment Amid $100B Funding Push 
ASML’s EUV Lithography Machines Power Europe’s Most Valuable Tech Company 
Sandisk Stock Soars After Blowout Earnings and AI-Driven Outlook 
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns 
CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs 
Volkswagen CEO Oliver Blume Faces Crucial Year as Investors Demand Turnaround Results 
Elon Musk’s SpaceX Explores Merger Options With Tesla or xAI, Reports Say 
Apple Earnings Beat Expectations as iPhone Sales Surge to Four-Year High 
Apple Faces Margin Pressure as Memory Chip Prices Surge Amid AI Boom 
Woodside Energy Flags Lower 2026 Production Outlook Despite Strong Q4 Revenue Beat 
SAN DIEGO, May 23, 2017 -- Retrophin, Inc. (NASDAQ:RTRX) today announced that Stephen Aselage, chief executive officer, will present at the Jefferies 2017 Global Healthcare Conference in New York City on Tuesday, June 6, 2017 at 3:30 p.m. ET.
A live webcast of the presentation will be available at http://ir.retrophin.com/events.cfm and an archived replay will be accessible for up to 30 days.
About Retrophin
Retrophin is a fully integrated biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options. The Company’s approach centers on its pipeline featuring late-stage assets targeting rare diseases with significant unmet medical needs, including sparsentan for focal segmental glomerulosclerosis (FSGS), a disorder characterized by progressive scarring of the kidney often leading to end-stage renal disease, and RE-024 for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood. Research exploring the potential of early-stage assets in several rare diseases is also underway. Retrophin’s R&D efforts are supported by revenues from the Company’s commercial products Thiola®, Cholbam®, and Chenodal®.
Contact: Chris Cline, CFA Vice President, Investor Relations & Corporate Communications 646-564-3680 [email protected]
